A study to compare the efficacy and adverse effects of metformin versus myoinositol plus d-chiroinositol combination therapy in polycystic ovarian syndrome

A prospective randomised comparative study of metformin versus myoinositol plus d-chiroinositol combination therapy in polycystic ovarian syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/018306

Enrollment

Registered

2019-03-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Metformin: Metformin 500 mg BD daily to one group Control Intervention1: Myoinositol plus d-chiroinositol: Myoinositol plus d-chiroinositol combination therapy 1000 mg BD daily to other

Eligibility

Inclusion criteria

Inclusion criteria: Women fulfilling 2 out of 3 criteria of Rotterdam criteria Oligo menorrhea and/or Anovulation Clinical and/or hormonal parameters of hyperandrogenism that may be associated with Hirsutism Polycystic ovaries in ultrasound findings

Exclusion criteria

Exclusion criteria: Women with pre-existing endocrine disorder History of Hypertension & Diabetes Mellitus Women who received previous treatment with other drugs within last 6 months Pregnancy

Design outcomes

Primary

Measure	Time frame
To evaluate the changes in the hormone levels of LH, FSH, AMH, testosterone, insulin, progesterone, estrogen and regularity of menstrual cycle after giving the interventional treatment.Timepoint: 3,6,9 months	—

Secondary

Measure	Time frame
To evaluate the adverse effects of both treatmentsTimepoint: 3,6,9 months	—

Countries

India

Contacts

Public ContactDr Sukhmani Jaura

Government Medical College, Amritsar

drjatindersingh@gmail.com9876118935

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026